Outcomes of total hip arthroplasty in calcium pyrophosphate deposition disease patients

Semin Arthritis Rheum. 2023 Dec:63:152300. doi: 10.1016/j.semarthrit.2023.152300. Epub 2023 Nov 4.

Abstract

Objective: We aim to examine the demographics, clinical characteristics, outcomes, and resource utilization following total hip arthroplasty (THA) in patients with and without calcium pyrophosphate deposition (CPPD) disease.

Methods: We queried the National Inpatient Sample database to identify patients who underwent THA between 2006 and 2014. The ICD-9 code 81.51 was used to determine the patients who underwent THA, and of those, we classified 2 groups of patients: (i) those with ICD-9 codes defining CPPD and (ii) those without any CPPD code. Data collection included patient demographics and comorbidities. Outcomes post-THA were mortality, length of stay (LOS), and costs. Associations between CPPD and specific morbidity were evaluated with chi-square tests. T tests were used for continuous variables.

Results: Among the 4,111,808 patients who underwent THA, 6198 (0.15 %) had CPPD, with a mean age of 77 years and 64.2 % were females. CPPD patients were more likely to be older (mean age 77 vs 72.7 years; p<0.001) than non-CPPD patients. The Charlson Comorbidity Index score ≥ 2 was more frequently seen in CPPD, however, the mortality post-THA was lower in the CPPD patients (0.7 % vs 1.7 %, OR 0.35, 95 % CI 0.26- 0.47). THA in CPPD patients was associated with a longer mean length of stay (LOS) (6.04 vs 5.15 days, OR 1.15, 95 % CI 1.09-1.22) while mean total charges were not statistically different between the 2 groups (p = 0.344). CPPD patients were more likely to be discharged to rehabilitation or other nursing facilities (42.5 % vs 35.3 %, p<0.001). The number of THA procedures increased in both CPPD and non-CPPD patients over time.

Conclusions: CPPD patients who underwent THA were more likely to be older, with a greater comorbidity burden, longer LOS and discharged to a non-home setting.

Keywords: CPPD; Calcium pyrophosphate deposition disease; Chondrocalcinosis; Healthcare utilization; Hip arthroplasty; Hip replacement.

MeSH terms

  • Aged
  • Arthroplasty, Replacement, Hip*
  • Calcium Pyrophosphate
  • Chondrocalcinosis*
  • Female
  • Humans
  • Inpatients
  • Length of Stay
  • Male
  • Postoperative Complications / epidemiology
  • Retrospective Studies
  • Risk Factors

Substances

  • Calcium Pyrophosphate
  • diphosphoric acid